BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28452416)

  • 1. Low CREBBP expression is associated with adverse long-term outcomes in paediatric acute lymphoblastic leukaemia.
    Gao C; Zhang RD; Liu SG; Zhao XX; Cui L; Yue ZX; Li WJ; Chen ZP; Li ZG; Rao Q; Wang M; Zheng HY; Wang JX
    Eur J Haematol; 2017 Aug; 99(2):150-159. PubMed ID: 28452416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOTCH1 mutations are associated with favourable long-term prognosis in paediatric T-cell acute lymphoblastic leukaemia: a retrospective study of patients treated on BCH-2003 and CCLG-2008 protocol in China.
    Gao C; Liu SG; Zhang RD; Li WJ; Zhao XX; Cui L; Wu MY; Zheng HY; Li ZG
    Br J Haematol; 2014 Jul; 166(2):221-8. PubMed ID: 24690100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
    Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
    Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of the efficacy of two chemotherapy protocols for children with TEL-AML1[STBZ] fusion gene positive acute lymphoblastic leukemia].
    Wang KL; Mei YY; Cui L; Gao C; Liu FF; Zhao XX; Li WJ; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Wu MY; Zhou X; Li ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):285-90. PubMed ID: 24762993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
    Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
    [No Abstract]   [Full Text] [Related]  

  • 7. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
    Gao C; Zhao XX; Li WJ; Cui L; Zhao W; Liu SG; Yue ZX; Jiao Y; Wu MY; Li ZG
    Am J Hematol; 2012 Nov; 87(11):1022-7. PubMed ID: 22911440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in childhood acute lymphoblastic leukemia.
    Jia M; Zhao HZ; Shen HP; Cheng YP; Luo ZB; Li SS; Zhang JY; Tang YM
    Int J Lab Hematol; 2015 Oct; 37(5):631-40. PubMed ID: 25955539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E2F3a gene expression has prognostic significance in childhood acute lymphoblastic leukemia.
    Wang KL; Mei YY; Cui L; Zhao XX; Li WJ; Gao C; Liu SG; Jiao Y; Liu FF; Wu MY; Ding W; Li ZG
    Eur J Haematol; 2014 Oct; 93(4):281-9. PubMed ID: 24758291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
    Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
    J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experience and results of acute lymphoblastic leukaemia treatment in children between 1989-2005 in Navarre].
    Molina J; Molins T; Gil FJ; Sagaseta de Ilurdoz M; Ruipérez E; Guembero E; Sala F; Valiente A; Labaca MA
    An Sist Sanit Navar; 2007; 30(3):363-71. PubMed ID: 18227893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical effect of CCLG-ALL2008 regimen in treatment of children and adolescents aged >10 years with acute lymphoblastic leukemia].
    Lan Y; Chen XJ; Zou Y; Ruan M; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2019 May; 21(5):405-410. PubMed ID: 31104652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-Term Outcome of 940 Children with Newly Diagnosed Acute Lymphoblastic Leukemia Treated with CCLG-ALL 2008: A Prospective Single Center Study in China].
    Zou Y; Chen XJ; Liu XM; Guo Y; Yang WY; Chen YM; Zhang L; Zhu XF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1075-1080. PubMed ID: 32798380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
    Dixon ZA; Nicholson L; Zeppetzauer M; Matheson E; Sinclair P; Harrison CJ; Irving JA
    Haematologica; 2017 Apr; 102(4):736-745. PubMed ID: 27979926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Predictors and Prognostic Model for Pediatric Lymphoblastic Lymphoma Treated With Uniform BFM90 Protocol: A Single-Center Experience of 65 Patients From Asia.
    Patel A; Tiwari A; Biswas B; Chand Sharma M; Vishnubhatla S; Bakhshi S
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e291-e298. PubMed ID: 30905539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
    Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
    Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups.
    Attarbaschi A; Morak M; Cario G; Cazzaniga G; Ensor HM; te Kronnie T; Bradtke J; Mann G; Vendramini E; Palmi C; Schwab C; Russell LJ; Schrappe M; Conter V; Mitchell CD; Strehl S; Zimmermann M; Pötschger U; Harrison CJ; Stanulla M; Panzer-Grümayer R; Haas OA; Moorman AV;
    Br J Haematol; 2012 Sep; 158(6):772-7. PubMed ID: 22816614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.